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The  rapid speed  of  kill  of sarolaner  (SimparicaTM, Zoetis),  a novel  isoxazoline  compound,  was  demon-
strated  against  three  tick  species  known  to infest  dogs  in Europe  or the  United  States.  Efﬁcacy  was
measured  against  an existing  infestation  and  against  subsequent  weekly  re-infestations  for  35 days  after
treatment.
Dogs were  randomly  allocated  to  treatment  with  a single  oral  dose  of  either  placebo  or  sarolaner
(2  mg/kg)  based  on  pre-treatment  host-suitability  tick  counts.  Dogs  were  infested  with  approximately
50  unfed  adult  Ixodes  scapularis,  Ixodes  ricinus  or Amblyomma  maculatum  ticks  on  Days—2,  7,  14, 21, 28
and  35.  Tick  counts  were  conducted  at 4  (I.  scapularis  only),  8, 12  and  24  h after  treatment  on  Day  0  and
after  each  subsequent  re-infestation.
No treatment-related  adverse  reactions  occurred  during  any  of these  studies.  Dogs  in  the
placebo-treated  groups  maintained  adequate  tick  infestations  (recovery  of 20–70%  of  applied  ticks)
throughout  the  duration  of the  studies.  Following  treatment,  live  tick  counts  were  signiﬁcantly
reduced relative  to placebo  at the  8 h  post  treatment  counts  indicating  that  sarolaner  started
killing  existing  infestations  of  ticks  rapidly  after  treatment.  Efﬁcacy  was  90.1%  against  I.  ricinus,
98.8%  against  I. scapularis,  and  99.2%  against  A.  maculatum  within  12 h, and  100%  efﬁcacy  was
achieved  at  24  h  after  treatment  against  all three  tick  species.  This  speed  of  kill  was  maintained
throughout  the  month  with  ≥95.7%,  ≥98.7%  and ≥89.6%  efﬁcacy  against  I.  scapularis,  I. ricinus,  and  A.
maculatum,  respectively,  at 24  h after  re-infestation  at least  through  Day 28.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Amyblyomma maculatum (Gulf Coast tick) and Ixodes scapularis
black legged or deer tick) are tick species that infest dogs in the
nited States. Ixodes ricinus (castor bean or sheep tick) is an impor-
ant species infesting dogs in Europe (Chomel, 2011). Most ticks
hat infest dogs and cats, including the genera Amblyomma and
xodes,  use an ambush technique called questing to locate the host;
he ticks crawl onto weeds, grasses, bushes or other leafy vegeta-
ion, extend their forelegs, which contain a sensory apparatus called
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/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a Haller organ, and wait for the host to brush against the vegeta-
tion. When this occurs, the tick releases from the vegetation and
crawls onto the host (Dryden and Payne, 2004). The ticks use their
chelicerae to cut the dermis and insert their hypostome containing
backward directed spikes. Many ticks reinforce this attachment by
secreting a cement-like substance from the salivary glands. Once
the attachment is secure, the tick begins its slow blood-feeding
phase which may  last for several days. The slow feeding phase is fol-
lowed by the rapid feeding phase. During the rapid feeding phase,
which occurs 12–36 h before the tick detaches from the host, the
mated female may  increase dramatically in size often reaching up
to one hundred times her unfed body weight (Blagburn and Dryden,
2009).
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Blood feeding by ticks can cause irritation, debilitation through
lood loss, and paralysis or death from the section of salivary
oxins. In addition, ticks are vectors for a number of serious
athogens affecting dogs, man  and other animals. In the United
tates, A. maculatum is known to transmit Rickettsia parkeri, a
potted fever group rickettsia recently found to be pathogenic to
umans, resulting in an eschar-producing febrile illness (Jiang et al.,
012; Chomel, 2011). This tick also transmits Hepatozoon ameri-
anum, which causes American canine hepatozoonosis, though the
og must ingest the tick to become infected (Ewing and Panciera,
003; Blagburn and Dryden, 2009). Ixodes scapularis is the main
ector of Borrelia burgdorferi sensu lato (Lyme disease) in the
nited States and is also the vector of Anaplasma phagocytophilum
causes anaplasmosis in humans and canines) and Babesia micro-
is (causes human babesiosis). Both A. maculatum and I. scapularis
ay  also cause tick paralysis (Blagburn and Dryden, 2009) which
an affect birds, reptiles, humans, dogs, and a wide variety of
ther mammals. In Europe, Ixodes ricinus is the main vector of
. burgdorferi sensu lato and is also the vector of the tick borne
ncephalitis virus as well as a number of other pathogens of humans
nd domestic animals (Jaenson et al., 2012). Reports from Asia,
urope, and the United States have documented Bartonell hense-
ae DNA in Ixodes spp. and while pathogen transfer has not been
onﬁrmed in dogs, a recent study showed I. ricinus to be a com-
etent vector of Bartonella birtlesii in a murine model (Reis et al.,
011).
In the past two decades, throughout the United States and
urope, the tick population in established regions has become
ore abundant and the geographical distribution has continued to
xpand (Jaenson et al., 2012; Leighton et al., 2012). This change can
e explained by two main factors: ﬁrst, the high availability of large
umbers of important tick maintenance hosts, second, a warmer
limate with milder winters and a prolonged growing season that
ermits greater survival and proliferation over a larger geographi-
al area of both the tick itself and its hosts (Blagburn and Dryden,
009; Jaenson et al., 2012; Lindgren et al., 2000). The increase in
he tick population means that humans and their pets are encoun-
ering more ticks and are exposed to more ticks per encounter and
hat pet owners are seeing more ticks on their pets than in the past.
umerous studies support the efﬁcacy of host targeted tick control
roducts (Dryden, 2009). The successful transmission of tick borne
iseases to the host may  require a prolonged period of attachment
sually 24–48 h or longer (Little, 2007), though for some rickettsial
athogens transmission may  possibly occur within as little as 4 h
Nicholson et al., 2010). Thus a product’s speed of kill, deﬁned as the
ime required to kill ticks that are already attached or to kill ticks
fter re-infestation, is key in the selection of an acaricide to reduce
 dog’s potential risk of contracting tick-borne diseases. Addition-
lly, products with rapid efﬁcacy are more effective in ameliorating
he irritation and debilitating effects due to blood loss or tick
oxicosis.
A new class of ectoparasitics, the isoxazolines, have shown
xcellent efﬁcacy against ﬂeas and ticks following oral adminis-
ration (Rohdich et al., 2014; Shoop et al., 2014). Sarolaner is a new,
otent isoxazoline that provides treatment and month long con-
rol of ticks and ﬂeas on dogs following a single oral dose (McTier
t al., 2016). Laboratory studies conﬁrmed the excellent efﬁcacy of
arolaner for the entire month against the major species of ticks
nfesting dogs in the EU and US (Geurden et al., 2016; Six et al.,
016). As the speed of kill and consequent interruption of feeding
s critical for acaricides to reduce the chances of transmission of
ick-borne diseases, laboratory studies were conducted to evaluate
he speed of kill of sarolaner against three tick species (I. scapu-
aris, I. ricinus and A. maculatum) for a period of ﬁve weeks after
reatment.tology 222 (2016) 37–42
2. Materials and methods
Three laboratory studies were conducted in purpose bred dogs
to evaluate the speed of kill of the minimum single oral dose of
2 mg/kg bodyweight sarolaner against induced tick infestations and
weekly challenges up to 35 days post treatment. Efﬁcacy against I.
scapularis was  evaluated at a research facility in Sugar Land, Texas.
The I. ricinius study was  carried out in Glenamoy, Ireland and the
study with A. maculatum was  conducted in Greenbrier, Arkansas.
All studies were conducted in accordance with the World Asso-
ciation for the Advancement of Veterinary Parasitology (WAAVP)
guidelines for evaluating the efﬁcacy of parasiticides for the treat-
ment, prevention and control of ﬂea and tick infestation on dogs
and cats (Marchiondo et al., 2013) and complied with Good Clini-
cal Practice, (EMEA, 2000). Protocols were reviewed and approved
by the local and or Zoetis Institutional Animal Care and Use  Com-
mittee. Masking of all studies was assured through the separation
of functions with all personnel conducting observations or animal
care or performing infestations and counts masked to treatment
allocation.
2.1. Animals
Purpose bred Beagle and mongrel dogs of both sexes, aged 6
months to 7.5 years and weighing 6.0–26.0 kg were used. All dogs
had not been treated with an ectoparasiticide for at least 60 days or
demonstrated good tick retention (recovery of at least 25% of the
applied ticks at 48 h after infestation) prior to treatment and were
in good health at enrolment. Each dog was individually identiﬁed
by a unique microchip or ear tattoo. Dogs were individually housed
in indoor pens such that no physical contact was  possible between
dogs from Day 0 to the end of the study. Dogs were fed an appro-
priate maintenance ration of a commercial dry canine feed for the
duration of the study. Water was available ad libitum.
2.2. Experimental design
Day 0 for each study was  the day dogs were administered the
study treatment. A physical exam was performed on each dog by a
veterinarian to determine health and suitability prior to inclusion
in the study. Dogs were acclimatized for a minimum of 12 days
before treatment and general health observations were performed
twice daily from the start of the acclimation period to the end of
the study. All dogs were examined to ensure they were free of ticks
and were then infested between Day −9 and Day −6 to determine
host suitability. The number of live attached ticks present on each
dog was counted 48 (±2) hours after this infestation.
The studies followed a randomized, complete block design and
block was  based on the pre-treatment host-suitability tick counts
and pen location. For the I. scapularis and I. ricinus studies, there
were eight dogs per group. For A. maculatum,  seven dogs were allo-
cated per group. Dogs were ranked according to decreasing host
suitability tick counts and randomly allocated within blocks. In
the I. scapularis study, 64 dogs were ranked in blocks of eight and
assigned to one of four placebo or one of four sarolaner groups with
one group of each treatment assigned for tick counts at 4, 8, 12 or
24 h after treatment and subsequent tick infestations on Days 7, 14,
21, 28 and 35. In the I. ricinus study, 48 dogs were ranked in blocks
of six and assigned to one of three placebo or one of three sarolaner
groups with one group of each treatment assigned for tick counts
at 8, 12 or 24 h after treatment or subsequent tick infestations on
Days 7, 14, 21, 28 and 35. In the A. maculatum study, 42 dogs were
assigned to one of one of three placebo or one of three sarolaner
groups with one group of each treatment assigned for tick counts
at 8, 12 or 24 h after treatment or subsequent tick infestations on
Days 7, 14, 21, 28 and 35.
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For tick infestations (Days −2, 7, 14, 21, 28 and 35), dogs were
anually held or sedated (I. ricinus)  and a pre-counted aliquot of
pproximately 50 (1:1 sex ratio, 3:2 female:male was used for I.
icinus to increase the chances of >25% retention rate in untreated
ogs) adult unfed ticks were placed onto the hair coat and allowed
o disperse on the dog. The dogs infested with A. maculatum were
laced in travel crates for 2–4 h after infestation to restrict the dogs’
ovement and facilitate tick attachment.
Tick counts were performed by personnel trained in the
tandard procedures in use at the test facility. Protective
loves and clothing were changed between dogs to prevent
ross-contamination. Personnel conducting parasite or other
bservations were unaware of treatment assignments, and dogs
ere examined in a non-systematic order. Initially, the dog’s entire
ody was examined, pushing the hair against its natural nap, expos-
ng, counting and removing the ticks. After the manual inspection,
n extra-ﬁne tooth comb was used to comb the animal to remove
ny otherwise missed ticks. Each dog was examined for at least
0 min. If ticks were encountered in the last minute, combing was
ontinued in one minute increments until no ticks were encoun-
ered. The ticks were examined to assess viability and the numbers
f live ticks were quantiﬁed.
.3. Treatment administration
Dose selection was made based on bodyweights measured on
ay—2. Dogs were dosed with from one to three tablets (placebo or
arolaner (SimparicaTM chewable tablets, Zoetis) strengths of 5, 10,
0, or 40 mg)  such that the sarolaner dose was as close as possible
o the minimum label dosage of 2 mg/kg without under-dosing.
ogs were hand-pilled to ensure accurate dose delivery. Food was
ffered prior to and after dosing. Dogs were observed for general
ealth and any reaction to treatment approximately 1, 3 and 6 h
fter treatment.
.4. Ticks
Ticks were considered pathogen free, as the unfed adult ticks
sed in the studies had been maintained for at least one generation
n the colonies on pathogen-free hosts. The I. scapularis ticks were
rom a colony initiated with wild caught ticks from Oklahoma and
ocally collected ticks are introduced into the colony at least once
very two years. Ixodes ricinus were from a European colony that has
nnual introductions of wild caught ticks. The A. maculatum were
ooled from colonies in Oklahoma and Texas that both periodically
ntroduce new wild caught ticks.
.5. Data analysis
The individual dog was the experimental unit and the primary
ndpoint was live tick counts. Tick counts were transformed by the
oge(count + 1) transformation prior to analysis in order to stabilize
he variance and normalize the data. Using the PROC MIXED proce-
ure (SAS 9.2, Cary NC), transformed counts were analyzed using a
ixed linear model. The ﬁxed effect was treatment group and the
andom effects were room and block within room at each time-
oint [in the I. ricinus study, the random effect was block at each
imepoint]. Testing was two-sided at the signiﬁcance level ˛=0.05.
ercent efﬁcacy was calculated using Abbott’s formula:reduction = 100 × mean count (placebo) −  mean count (treated)
mean count (placebo)tology 222 (2016) 37–42 39
3. Results
3.1. Efﬁcacy
Placebo-treated dogs maintained I. scapularis tick infestations
throughout the study (Table 1) with approximately 25–50% of the
applied infestation recovered at each time-point. The 4-hour time-
point was assessed for I. scapularis as it was expected to be the
species most rapidly affected by sarolaner treatment, since it tends
to attach and initiate feeding faster than the other species. How-
ever, at 4 h there was  no signiﬁcant reduction in live tick counts
compared with placebo (P > 0.05, Table 1), therefore this time-
point was not evaluated for the other two  species. Geometric mean
live tick counts for sarolaner-treated dogs were signiﬁcantly lower
than placebo within 8 h after treatment on Day 0 (P = 0.0002), and
within 12 h after re-infestations on Days 7–28 (P ≤ 0.0019). Fol-
lowing the Day 35 infestation, counts were signiﬁcantly lower by
24 h (P ≤ 0.0001). Efﬁcacy for sarolaner-treated dogs was  98.8% and
100% at 12 and 24 h respectively after treatment, and ≥95.7% by 24 h
after infestation on Days 7, 14, 21 and 28, and 74.9% on Day 35.
Placebo-treated dogs maintained I. ricinus infestations through-
out the study (Table 2) with approximately 35–50% of the applied
infestation recovered at each time-point. Geometric mean live tick
counts for sarolaner-treated dogs were signiﬁcantly lower than
placebo within 8 h after treatment on Day 0 (P = 0.0003) and after
re-infestations on Days 7–28 (P ≤ 0.0409). Following the Day 35
infestation, counts were signiﬁcantly lower by 12 h (P = 0.0022).
Efﬁcacy for sarolaner-treated dogs was  90.1% and 100% at 12 and
24 h respectively after treatment, ≥94.9% by 12 h after infestation
on Days 7, 14, 21 and 28, and 95.2% at 24 h on Day 35.
Placebo-treated dogs maintained A. maculatum tick infestations
throughout the study (Table 3) with approximately 20–70% of the
applied infestation recovered at each time-point. Geometric mean
live tick counts for sarolaner-treated dogs were signiﬁcantly lower
than placebo within 8 h after treatment on Day 0 (P ≤ 0.0001) and at
12 h after re-infestations on Days 7and 35 (P ≤ 0.0028), and within
24 h after re-infestations on Days 14, 21 and 28 (P ≤ 0.0001). Efﬁ-
cacy for sarolaner-treated dogs was  99.2% and 100% at 12 and 24 h
respectively after treatment, and ≥94.1% by 24 h after infestation
on Days 7, 14, 21 and 35, and 89.6% on Day 28.
3.2. Safety
There were no adverse events observed in any of the studies that
were considered related to sarolaner treatment.
4. Discussion
In these studies, sarolaner demonstrated a rapid speed of kill
against existing and subsequent re-infestations of ticks. This con-
sistent and rapid persistent speed of kill against new infestations is
notable when the biology of the ticks is considered, as counts were
conducted soon after infestation and during this period the ticks
had to disperse, penetrate the haircoat, attach, and begin feeding
in order to ingest an effective dose.
The sustained efﬁcacy against these tick species for up to 35 days
is consistent with the results of dose conﬁrmation studies which
reported ongoing effectiveness through Day 35 when assessed at
48 h after treatment or re-infestation (Geurden et al., 2016; Six et al.,
2016). The speed of kill and persistent efﬁcacy of sarolaner is also
comparable to those reported for some common marketed spot-on
formulations (Baker et al., 2011; Endris et al., 2003; Bonneau et al.,
2010; Baggott et al., 2011).
In these studies, live tick counts were signiﬁcantly reduced rel-
ative to placebo at the 8 h counts, indicating that sarolaner quickly
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Table  1
Geometric and (arithmetic) mean Ixodes scapularis (black legged tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls at
various times after treatment and re-infestation for dogs treated once orally with sarolaner at 2 mg/kg.
Placebo Sarolaner
Daya Hourb Mean Range Mean Range Efﬁcacyc (%) P value*
0 4 18.2 (18.8) 11–25 21.4 (23.6) 8–36 0.0 0.4174
8  17.4 (19.9) 6–34 7.6 (8.8) 2–17 56.5 (56.0) 0.0002
12  24.1 (25.0) 16–40 0.3 (0.4) 0–1 98.8 (98.5) <0.0001
24  17.2 (17.4) 14–21 0.0 (0.0) 0–0 100 <0.0001
7  4 20.0 (20.9) 11–28 17.0 (18.0) 10–29 15.0 (13.8) 0.5060
8  11.0 (13.3) 5–28 11.8 (14.3) 5–24 0.0 0.7795
12  20.6 (22.4) 7–32 1.7 (1.9) 1–4 91.7 (91.6) <0.0001
24  13.3 (14.6) 5–24 0.0 (0.0) 0–0 100 <0.0001
14  4 21.5 (23.3) 11–36 17.1 (19.3) 6–36 20.7 (17.1) 0.4649
8  12.4 (16.4) 2–33 13.6 (16.6) 4–30 0.0 0.7891
12  9.8 (10.9) 4–19 3.0 (4.3) 0–11 68.8 (60.9) 0.0019
24  11.1 (12.1) 5–19 0.1 (0.3) 0–2 98.7 (97.9) <0.0001
21  4 19.1 (20.1) 12–31 23.7 (25.4) 9–36 0.0 0.3734
8  12.7 (13.9) 5–24 18.1 (20.9) 7–34 0.0 0.1511
12  19.5 (19.9) 14–27 5.1 (6.1) 2–14 74.0 (69.2) <0.0001
24  11.4 (13.9) 4–28 0.5 (0.6) 0–2 95.7 (95.5) <0.0001
28  4 21.0 (23.9) 4–34 19.0 (20.4) 8–29 9.5 (14.7) 0.7129
8  18.2 (20.9) 5–37 16.5 (18.0) 8–36 9.6 (13.8) 0.7121
12  27.3 (29.3) 11–44 10.4 (11.3) 6–19 62.0 (61.5) 0.0008
24  16.5 (17.5) 8–25 0.5 (1.0) 0–6 97.2 (94.3) <0.0001
35  4 16.2 (18.0) 8–38 21.2 (21.9) 12–28 0.0 0.3357
8  14.0 (16.8) 5–31 16.8 (18.1) 8–33 0.0 0.5232
12  15.5 (16.8) 7–24 12.8 (14.8) 3–25 17.6 (11.9) 0.4966
24  13.1 (14.4) 4–24 3.3 (4.6) 0–13 74.9 (67.8) <0.0001
a Day of treatment (0) and subsequent weekly tick infestations.
b Time after treatment or subsequent weekly tick infestations.
c Efﬁcacy relative to placebo based on geometric means; efﬁcacy based on arithmetic means is given in parentheses if different.
* P value for comparison of geometric mean tick counts within a row, P ≤ 0.05 indicates signiﬁcant difference.
Table 2
Geometric and arithmetic mean Ixodes ricinus (castor bean tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls at various
times  after treatment and re-infestation for dogs treated once orally with sarolaner at 2 mg/kg.
Placebo Sarolaner
Daya Hourb Mean Range Mean Range Efﬁcacyc (%) P value*
0 8 22.9 (23.1) 19–30 5.3 (7.6) 1–23 76.7 (67.0) 0.0003
12  19.8 (20.9) 8–28 2.0 (4.4) 0–14 90.1 (79.0) <0.0001
24  17.7 (20.4) 5–31 0.0 (0.0) 0–0 100 <0.0001
7  8 18.7 (19.3) 14–29 7.3 (9.0) 2–18 61.2 (53.2) 0.0001
12  17.9 (18.0) 15–21 0.5 (0.8) 0–4 97.5 (95.8) <0.0001
24  18.3 (19.0) 11–24 0.0 (0.0) 0–0 100 <0.0001
14  8 25.6 (26.0) 20–35 8.0(11.1) 1–27 65.5 (57.2) 0.0004
12  22.1 (22.3) 18–25 0.9 (2.0) 0–8 96.1 (91.0) <0.0001
24  21.0 (21.3) 17–28 0.0 (0.0) 0–0 100 <0.0001
21  8 23.0 (23.4) 17–31 13.5 (15.4) 4–31 41.4 (34.2) 0.0409
12  23.3 (23.9) 17–32 0.8 (1.9) 0–10 96.6 (92.1) 0.0001
24  20.0 (20.9) 12–30 0.3 (0.4) 0–2 98.7 (98.2) <0.0001
28  8 24.8 (25.1) 17–31 19.0 (19.4) 4–31 23.2 (22.9) 0.0170
12  23.4 (23.6) 17–32 1.2 (1.8) 0–10 94.9 (92.6) <0.0001
24  18.1 (19.8) 12–30 0.2 (0.4) 0–2 99.0 (98.1) <0.0001
35  8 24.2 (24.8) 19–33 15.7 (17.8) 4–26 35.1 (28.3) 0.0922
12  23.1 (23.8) 13–30 7.4 (9.3) 2–26 67.9 (61.1) 0.0022
24  17.0 (18.1) 8–24 0.8 (1.6) 0–9 95.2 (91.0) <0.0001
a Day of treatment (0) and subsequent weekly tick infestations.
etic m
icates
s
t
I
t
tb Time after treatment or subsequent weekly tick infestations.
c Efﬁcacy relative to placebo based on geometric means; efﬁcacy based on arithm
* P value for comparison of geometric mean tick counts within a row, P ≤ 0.05 ind
tarted killing existing infestations of ticks resulting in rapid, effec-
ive control with efﬁcacy of 90.1% against I. ricinus,  98.8% against
. scapularis and 99.2% against A. maculatum within 12 h post-
reatment, and 100% efﬁcacy within 24 h post-treatment against all
hree tick species. This rapid speed of kill was maintained through-eans is given in parentheses if different.
 signiﬁcant difference.
out the month with ≥95.7%, ≥98.7% and ≥89.6% efﬁcacy against
I. scapularis, I. ricinus, and A. maculatum, respectively, at 24 h after
re-infestation at least through Day 28.
The increasing emergence of infection by zoonotic pathogens
transmitted through tick bites to dogs and humans has triggered a
R.H. Six et al. / Veterinary Parasitology 222 (2016) 37–42 41
Table  3
Geometric and arithmetic mean Amblyomma maculatum (Gulf Coast tick) counts and ranges for placebo control and treated dogs and percent efﬁcacy relative to controls at
various  times after treatment and re-infestation for dogs treated once orally with sarolaner at 2 mg/kg.
Placebo Sarolaner
Daya Hourb Mean Range Mean Range Efﬁcacyc (%) P value*
0 8 31.1 (33.1) 21–50 3.0 (6.6) 0–19 90.3 (80.2) <0.0001
12  27.1 (29.0) 13–44 0.2 (0.3) 0–1 99.2 (99.0) <0.0001
24  30.1 (32.1) 17–50 0.0 (0.0) 0–0 100 <0.0001
7  8 36.0 (36.9) 27–48 32.1 (33.3) 17–42 10.9 (9.7) 0.5895
12  30.5 (31.3) 22–45 15.1 (18.9) 5–43 50.3 (39.7) 0.0028
24  23.5 (25.6) 13–45 1.1 (1.4) 0–3 95.2 (94.4) <0.0001
14  8 37.6 (38.1) 29–50 28.5 (29.0) 20–39 24.3 (24.0) 0.0234
12  25.0 (26.4) 11–39 13.1 (16.9) 4–50 47.6 (36.2) 0.0768
24  9.7 (10.1) 6–14 0.2 (0.4) 0–3 97.8 (95.8) <0.0001
21  8 26.8 (28.4) 14–42 29.7 (31.1) 18–43 0.0 0.7902
12  10.5 (13.0) 1–25 16.6 (22.0) 4–47 0.0 0.2573
24  18.4 (20.9) 9–45 1.1 (2.4) 0–13 94.1 (88.4) <0.0001
28  8 29.9 (33.7) 10–50 22.5 (23.1) 16–32 24.9 (31.4) 0.2655
12  16.1 (17.3) 7–27 15.4 (17.9) 7–40 4.4 (0.0) 0.8638
24  17.0 (18.1) 10–29 1.8 (2.6) 0–7 89.6 (85.8) <0.0001
35  8 28.6 (32.1) 7–50 17.4 (19.1) 3–32 39.3 (39.6) 0.0837
12  29.8 (31.0) 13–50 10.2 (11.6) 2–20 65.9 (62.7) 0.0006
24  17.2 (17.0) 10–25 0.6 (0.7) 0–3 96.7 (95.8) <0.0001
aDay of treatment (0) and subsequent weekly tick infestations.
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Nb Time after treatment or subsequent weekly tick infestations.
c Efﬁcacy relative to placebo based on geometric means; efﬁcacy based on arithm
* P value for comparison of geometric mean tick counts within a row, P ≤ 0.05 ind
enewed interest in comparative medicine and the concept of ‘one
edicine/one health’ that unites human and veterinary sciences
hen addressing the epidemiology, treatment and prevention of
ick borne infections (Otranto et al., 2009a,b; Dantas-Torres et al.,
012). The use of an ectoparasiticide such as sarolaner, which has a
apid speed of kill that persists for one month or longer after treat-
ent, will be an important tool in the prevention and control of tick
orne disease. An initial attachment and feeding of at least 24–48 h
s required before transmission of many tick-borne pathogens can
ccur (Little, 2007; Salinas et al., 2010). If the infected ticks are
illed within that time period, the transmission may  be prevented
Wengenmayer et al., 2014). With its rapid speed of kill and sus-
ained high efﬁcacy within 24 h for a full month after a single dose,
arolaner is likely to effectively reduce the chances of ticks sur-
iving and/or feeding for this critical time period. Thus, the use of
arolaner in a tick-control program should also reduce the chances
f dogs becoming infected with tick-borne diseases, being affected
y tick paralysis, and minimize deleterious health effects associated
ith tick infestation. Conﬁrmatory studies using disease transmis-
ion models will be needed to deﬁnitively evaluate efﬁcacy against
he transmission of tick-borne pathogens.
. Conclusions
Sarolaner has a quick onset of action against A. maculatum, I.
capularis and I. ricinus, resulting in the rapid kill of existing and sub-
equent re-infestations of ticks for a month after a single oral dose of
 mg/kg. This rapid speed of kill and consistent and persistent efﬁ-
acy against ticks following oral administration makes sarolaner
 convenient and effective treatment for tick control. Used in a
ontrol program, sarolaner will reduce the impact of tick infesta-
ion and has the potential to reduce the risk of dogs contracting
ick-borne diseases or tick paralysis.onﬂict of interest
The studies reported here were funded by Zoetis, Florham Park,
J. RHS, TG, SPM, MRM,  and NS are current employees of Zoetis.eans is given in parentheses if different.
 signiﬁcant difference.
LC, WRE  and AM were investigators contracted for these studies.
All authors assisted with the design and conduct of the studies,
interpretation of the data and manuscript review. There were no
conﬂicting interests that could have inﬂuenced the conduct and
reporting of these studies.
References
Baggott, D., Ollagnier, C., Yoon, S.S., Collidor, N., Mallouk, Y., Cramer, L.G., 2011.
Efﬁcacy of a novel combination of ﬁpronil: amitraz and (S)-methoprene for
treatment and control of tick species infesting dogs in Europe. Vet. Parasitol.
179, 330–334.
Baker, C.F., Hunter, J.S., McCall, J.W., Young, D.R., Hair, J.A., Everett, W.,  Yoon, S.S.,
Irwin, J.P., Young, S.L., Cramer, L.G., 2011. Efﬁcacy of a novel topical
combination of ﬁpronil, amitraz and (S)-methoprene for treatment and control
of  induced infestations with four North American tick species (Dermacentor
variabilis, Ixodes scapularis,  Amblyomma americanum and Amblyomma
maculatum)  on dogs. Vet. Parasitol. 179, 324–329.
Blagburn, B.L., Dryden, M.W.,  2009. Biology, treatment and control of ﬂea and tick
infestations. Vet. Clin. Small Anim. 39, 1173–1200.
Bonneau, S., Gupta, S., Cadiergues, M.C., 2010. Comparative efﬁcacy of two ﬁpronil
spot-on formulations against experimental tick infestations (Ixodes ricinus) in
dogs. Parasitol. Res. 107, 735–739.
Chomel, B., 2011. Tick-borne infections in dogs—an emerging infectious threat.
Vet.  Parasitol. 179, 294–301.
Dantas-Torres, F., Chomel, B.B., Otranto, D., 2012. Ticks and tick-borne diseases: a
one health perspective. Trends Parasitol. 28, 437–446.
Dryden, M.W.,  Payne, P.A., 2004. Biology and control of ticks infesting dogs and
cats  in North America. Vet. Therap. 5, 139–154.
Dryden, M.W.,  2009. Fleas and tick control in the 21st century: challenges and
opportunities. Vet. Dermatol. 20, 435–440.
EMEA., 2000. Guideline on good clinical practice. VICH Topic GL9. http://www.
ema.europa.eu/docs/en GB/document library/Scientiﬁc guideline/2009/10/
WC500004343.pdf. (accessed 26.02.15).
Endris, R.G., Hair, J.A., Anderson, G., Rose, W.B., Disch, D., Meyer, J.A., 2003. Efﬁcacy
of  two 65% permethrin spot-on formulations against induced infestations of
Ctenocephalides felis (Insecta: siphonaptera) and Amblyomma americanum
(Acari: ixodidae) on beagles. Vet. Therap. 4, 47–55.
Ewing, S.A., Panciera, R.J., 2003. American canine hepatozoonosis. Clin. Microbiol.
Rev. 16, 688–697.
Geurden, T., Mahabir, S.P., Becskei, C., Six, R.H., 2016. Efﬁcacy of a novel oral
formulation of sarolaner against four common European tick species infesting
dogs. Vet. Parasitol. (This Edition).
Jaenson, T.G., Hjertqvist, M.,  Bergström, T., Lundkvist, A., 2012. Why  is tick-borne
encephalitis increasing? A review of the key factors causing the increasing
incidence of human TBE in Sweden. Parasit. Vectors 5, 184–197.
4  Parasi
J
L
L
L
M
M
N
O
formulation of sarolaner (SimparicaTM) against ﬁve common tick species
infesting dogs in the United States. Vet. Parasitol. (This Edition).
Wengenmayer, C., Williams, H., Zschiesche, E., Moritz, A., Langenstein, J., Roepke,2 R.H. Six et al. / Veterinary
iang, J., Stromdahl, E.Y., Richards, A.L., 2012. Detection of Rickettsia parkeri and
Candidatus Rickettsia andeanae in Amblyomma maculatum Gulf Coast ticks
collected from humans in the United States. Vector Borne Zoonotic Dis. 12,
175–182.
eighton, P.A., Kofﬁ, J.K., Pelcat, Y., Lindsay, L.R., Ogden, N.H., 2012. Predicting the
speed of tick invasion: an empirical model of range expansion for the Lyme
disease vector Ixodes scapularis in Canada. J. Appl. Ecol. 49, 457–464.
indgren, E., Tälleklint, L., Polfeldt, T., 2000. Impact of climatic change on the
northern latitude limit and population density of the disease-transmitting
European tick Ixodes ricinus.  Environ. Health Perspect. 108, 119–123.
ittle, S.E., 2007. Changing paradigms in understanding transmission of canine
tick-borne diseases: the role of interrupted feeding and intrastadial
transmission. In 2nd Canine Vector-Borne Disease (CVBD) Symposium, 30–34.
archiondo, A.A., Holdsworth, P.A., Fourie, L.J., Rugg, D., Hellmann, K., Snyder, D.E.,
Dryden, M.W.,  2013. World Association for the Advancement of Veterinary
Parasitology (W.A.A.V.P.) second edition: guidelines for evaluating the efﬁcacy
of  parasiticides for the treatment, prevention and control of ﬂea and tick
infestations on dogs and cats. Vet. Parasitol. 194, 84–97.
cTier, T.L., Chubb, N., Curtis, M.,  Hedges, L., Inskeep, G.A., Knauer, C.S., Menon, S.,
Mills, B., Pullins, A., Zinser, E., Woods, D.J., Meeus, P., 2016. Discovery of
sarolaner: a novel, orally administered, broad spectrum, isoxazoline
ectoparasiticide for dogs. Vet. Parasitol. (This Edition).
icholson, W.L., Allen, K.E., McQuiston, J.H., Breitschwerdt, E.B., Little, S.E., 2010.
The increasing recognition of rickettsial pathogens in dogs and people. Trends
Parasitol. 26, 205–212.
tranto, D., Dantas-Torres, F., Breitschwerdt, E.B., 2009a. Managing canine
vector-borne diseases of zoonotic concern: part one. Trends Parasitol. 25,
157–163.tology 222 (2016) 37–42
Otranto, D., Dantas-Torres, F., Breitschwerdt, E.B., 2009b. Managing canine
vector-borne diseases of zoonotic concern: part two. Trends Parasitol. 25,
228–235.
Reis, C., Cote, M.,  Le Rhun, D., Lecuelle, B., Levin, M.L., Vayssier-Taussat, M.,  Bonnet,
S.I.,  2011. Vector competence of the tick Ixodes ricinus for transmission of
Bartonella birtlesii. PLoS Negl. Trop. Dis. 5 (5), e1186, http://dx.doi.org/10.1371/
journal.pntd.0001186.
Rohdich, N., Roepke, R.K.A., Zschiesche, E., 2014. A randomized, blinded, controlled
and multi-centered ﬁeld study comparing the efﬁcacy and safety of BravectoTM
(ﬂuralaner) against FrontlineTM (ﬁpronil) in ﬂea- and tick-infested dogs.
Parasit. Vectors 7, 83–87.
Salinas, L.J., Greenﬁeld, R.A., Little, S.E., Voskuhl, G.W., 2010. Tickborne infections in
the  southern United States. Am. J. Med. Sci. 340, 194–201.
Shoop, W.L., Hartline, E.J., Gould, B.R., Waddell, M.E., McDowell, R.G., Kinney, J.B.,
Lahm, G.P., Long, J.K., Xu, M.,  Wagerle, T., Jones, G.S., Dietrich, R.F., Cordova, D.,
Schroeder, M.E., Rhoades, D.F., Benner, E.A., Confalone, P.N., 2014. Discovery
and mode of action of afoxolaner, a new isoxazoline parasiticide for dogs. Vet.
Parasitol. 201, 179–189.
Six, R.H., Everett, W.,  R, Young, D.R., Carter, L., Mahabir, S.P., Honsberger, N.A.,
Myers, M.R., Holzmer, S., Chapin, S., Rugg, J.J., 2016. Efﬁcacy of a novel oralR.K., Heckeroth, A.R., 2014. The speed of kill of ﬂuralaner (BravectoTM) against
Ixodes ricinus ticks on dogs. Parasit. Vectors 7, 525–529.
